ASX ANNOUNCEMENT Lumos Diagnostics Quarterly Activity Statement, Cash Flow and FebriDx® Commercial Update Key Highlights from the First Quarter of Financial Year 2027 • U.S. commercialisation of FebriDx® as of 11 October 2026 - 265 healthcare sites across 29 states 1 actively ordering and using...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
Watch Lumos Diagnostics' latest callLumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call · Replay · Apr 20Read the transcript of Lumos Diagnostics Holdings (ASX:LDX) Q3 2026 Earnings Call6ix is reading this filing.
Lumos Diagnostics Holdings Ltd. on 6ix
In the deck
Earlier from Lumos Diagnostics
- FebriDx Commercial Traction Continues Across US Accounts
- FY26 Full Year Results Announcement
- FY26 Appendix 4E
- Lumos Receives FebriDx Order from PHASE Scientific
- FebriDx Commercial Traction Across Priority US Accounts
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics